Publications by authors named "Keisuke Ae"

Background: Schwannoma is a common benign tumor. Most schwannomas are sporadic, but approximately 5% of schwannomas are multifocal. Schwannomas are sometimes present in a skip-like pattern on a single continuous peripheral nerve (Multiple schwannomas scattered on a single peripheral nerve: MSSPN).

View Article and Find Full Text PDF

Purpose: Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m [4g/m once on day 1, then 2g/m once on days 2-7] × six) to patients showing a poor response (PrRsp) to preoperative chemotherapy with methotrexate, doxorubicin, and cisplatin (MAP) improves their prognoses. In this Japan Clinical Oncology Group (JCOG) study, JCOG0905, we aimed to investigate the efficacy and safety of IF in patients with PrRsp.

Methods: JCOG0905 is a multicenter, open-label, multi-institutional, randomized trial.

View Article and Find Full Text PDF

Aims: The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.

Methods: With representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting's process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries.

View Article and Find Full Text PDF

Background In 2024, reimbursement for gemcitabine-docetaxel therapy (GEM-DOC; gemcitabine 900 mg/m on days 1 and 8 and docetaxel 70 mg/m on day 8 every 21 days, GEM 900-DOC 70) to treat recurrent/metastatic soft tissue sarcoma (STS) was made in Japan. Methods We retrospectively reviewed clinical records of advanced/metastatic STS patients who underwent off-label gemcitabine-containing chemotherapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research between February 2007 and October 2019. Results Of 115 enrolled patients, 51 were treated with GEM-DOC (26 patients received the dose as previously stated) and the other 64 with gemcitabine monotherapy.

View Article and Find Full Text PDF

sarcoma is rare and its clinical features remain unclear. Given the similarity in presentation, it is possible that previously reported cases of Ewing-like adamantinoma may have been sarcoma. The present case report describes a tumor in a 55-year-old man that was originally thought to be a Ewing-like adamantinoma, but was recently found to be an sarcoma following direct sequencing.

View Article and Find Full Text PDF

Background:  Soft tissue sarcomas (STS) are rare malignancies requiring extensive surgical resection, often leading to significant soft tissue defects. Flap reconstruction is crucial for restoring function and appearance. Recent reconstructive microsurgery advancements, including high-resolution indocyanine green (ICG) imaging and ultra-high frequency ultrasonography (UHFU), have revolutionized preoperative planning and intraoperative guidance.

View Article and Find Full Text PDF

Osteosarcoma (OS) is a primary malignant bone tumor primarily affecting children and adolescents. The lack of progress in drug development for OS is partly due to unidentified actionable oncogenic drivers common to OS. In this study, we demonstrate that copy number gains of MCL1 frequently occur in OS, leading to vulnerability to therapies based on Mcl-1 inhibitors.

View Article and Find Full Text PDF
Article Synopsis
  • * It aims to determine if having surgery followed by three courses of adjuvant chemotherapy is as effective as the standard approach of chemotherapy followed by surgery and then more chemotherapy.
  • * The trial is a large, randomized phase III study that began in November 2022 and seeks to confirm that the new treatment method is not inferior regarding overall survival rates.
View Article and Find Full Text PDF

Lipogenic and fibrous tumors are thought to originate from CD34-positive stromal fibroblastic/fibrocystic cells. Well-differentiated lipogenic tumors typically express CD34, whereas dedifferentiated liposarcoma (DDLPS) often loses it. We conducted survival analyses involving 59 patients with DDLPS.

View Article and Find Full Text PDF
Article Synopsis
  • * The Birmingham Orthopaedic Oncology Meeting in January 2024 gathered 300 experts from over 50 countries to reach global consensus on chondrosarcoma treatment and address challenges related to periprosthetic joint infection in cancer surgeries.
  • * The meeting aimed to not only resolve current controversies but also to encourage collaboration among specialists for future research that could improve patient outcomes worldwide.
View Article and Find Full Text PDF

Background/aim: High complication rates during the perioperative management of sarcomas around the pelvis have been reported; however, few include the detailed clinical course or complications in the late postoperative period. Radiotherapy is a multidisciplinary strategy for treating sarcomas. However, irradiated bone and soft tissues show a permanent loss of repair and immunocompetence.

View Article and Find Full Text PDF

Rationale: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is considered a reliable and indispensable imaging method when evaluating distant metastases and clinical staging of angiosarcomas. Here, we report 2 cases of angiosarcoma with bone metastases with "false negative" findings on 18F-FDG PET/CT.

Patient Concerns: Case 1, a 39-year-old woman, who had undergone mastectomy for primary angiosarcoma 2 years prior, presented with a 5-month history of right coxalgia.

View Article and Find Full Text PDF

This retrospective multicenter study aimed to analyze the clinical features and prognosis of 24 patients diagnosed with LGMS between 2002 and 2019 in the Japanese sarcoma network. Twenty-two cases were surgically treated and two cases were treated with radical radiotherapy (RT). The pathological margin was R0 in 14 cases, R1 in 7 cases, and R2 in 1 case.

View Article and Find Full Text PDF
Article Synopsis
  • Reconstruction after periacetabular bone tumor removal poses challenges between using large bone grafts or implants for walking function and opting for hip transposition, which has less risk but variable results.
  • The study aims to assess recovery time for walking function after hip transposition, identify factors influencing early recovery, and examine if quick recovery correlates with improved walking ability and higher MSTS scores.
  • A retrospective review included 48 patients over a decade, focusing on those treated with hip transposition, with 38 patients monitored for at least 6 months to evaluate their functional recovery post-surgery.
View Article and Find Full Text PDF

Alveolar soft part sarcoma (ASPS) is a soft part malignancy affecting adolescents and young adults. ASPS is characterized by a highly integrated vascular network, and its high metastatic potential indicates the importance of ASPS's prominent angiogenic activity. Here, we find that the expression of ASPSCR1::TFE3, the fusion transcription factor causatively associated with ASPS, is dispensable for in vitro tumor maintenance; however, it is required for in vivo tumor development via angiogenesis.

View Article and Find Full Text PDF

Aims: Angiofibroma of soft tissue (AFST) is a benign tumour characterised by prominent arborizing blood vessels throughout the lesion. Approximately two-thirds of AFST cases were reported to have AHRR::NCOA2 fusion, and only two cases have been reported to have other gene fusions: GTF2I::NCOA2 or GAB1::ABL1. Although AFST is included in fibroblastic and myofibroblastic tumours in the World Health Organization's 2020 classification, histiocytic markers, especially CD163, have been reported to be positive in almost all examined cases, and it still remains the possibility of a fibrohistiocytic nature of the tumour.

View Article and Find Full Text PDF

Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was <6 months. Some patients can achieve long-term disease control with this treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Carbon ion radiotherapy (CIRT) is being investigated as a treatment for malignant pelvic tumors, especially for patients who cannot undergo surgery due to high risks.
  • The study involved 28 patients treated with CIRT and 69 control patients who underwent surgery, comparing their complication rates and functional outcomes over time.
  • Results indicated that CIRT had fewer early complications but more late complications, while functional outcomes remained stable with CIRT in the short term, contrasting with a decline in the surgery group that later rebounded, leading to similar mid-term outcomes between the two treatments.
View Article and Find Full Text PDF

NTRK-rearranged spindle cell neoplasms (NTRK-RSCNs) are a new category of soft tissue tumors with gene fusions. The present study aimed to investigate the radiological features of NTRK-RSCNs and their association with histopathological findings. The present study included six patients with NTRK-RSCNs, whose fusion genes were confirmed using next-generation sequencing.

View Article and Find Full Text PDF

Background: Extra-abdominal desmoid tumors often occur in the necks, shoulder, chest wall, back, arm, buttock, thigh and leg. Multicentric extra-abdominal desmoids are rather rare and seem to have other clinical features. The aim of our study was to investigate clinical features, especially multicentric occurrence of extra-abdominal desmoid tumors.

View Article and Find Full Text PDF

Background/aim: Trabectedin and eribulin are widely used for the treatment of soft-tissue sarcoma (STS). Previously it was shown that the baseline neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of eribulin for STS. However, prognostic factors for trabectedin on STS have not been identified to date.

View Article and Find Full Text PDF
Article Synopsis
  • Osteosarcoma, a common bone cancer in kids, has a poor prognosis, especially when it spreads to the lungs, highlighting the need for new treatments targeting both tumor growth and metastasis.
  • This study developed a humanized anti-PDPN antibody, which interacts with platelets and promotes tumor growth, and evaluated its effects on osteosarcoma cell lines and models.
  • The results showed that the new antibody significantly reduced tumor growth and metastasis in models expressing PDPN, offering a promising new strategy for treating PDPN-positive osteosarcoma without harmful side effects.
View Article and Find Full Text PDF
Article Synopsis
  • - The guidelines aim to provide evidence-based recommendations for improving the diagnosis, treatment, and prognosis of patients with soft tissue tumors.
  • - A multidisciplinary team created 22 clinical questions (CQs) and developed guidelines based on systematic reviews of evidence and expert input, following specific development methods.
  • - The recommendations are designed to help healthcare professionals make better decisions in treating soft tissue tumors, ultimately enhancing patient care in this area.
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness of systemic chemotherapy in patients with recurrent or metastatic soft tissue sarcoma (STS), specifically comparing those with tumors in the retroperitoneum/intra-abdomen to those in extremities/trunk.
  • A total of 49 patients with retroperitoneal/intra-abdominal STS and 75 patients with extremity/trunk STS were analyzed, revealing differences in tumor types and chemotherapy regimen, such as a higher usage of doxorubicin in the retroperitoneal cohort.
  • Despite these differences, the overall survival rates from salvage chemotherapy were similar between the two groups, with median survival times of approximately 31.9 months for the retroperitoneal cohort and 27
View Article and Find Full Text PDF